Todd W Vanderah

Dr. Todd W Vanderah

University of Arizona College of Medicine – Tucson, Tucson, AZ, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Current Opinion in Supportive & Palliative Care
Verified
Journal Article
Closed access
HEHolly M. Ellingson
Holly M. Ellingson
Todd W VanderahTodd W Vanderah
Todd W Vanderah
Purpose of review: The treatment of cancer-induced bone pain (CIBP) has been proven ineffective and relies heavily on opioids, the target of highly visible criticism for their negative side effects. Alternative therapeutic agents are needed and the last few years have brought promising results, detailed in this review. Recent findings: Cysteine/glutamate antiporter system, x c −, cannabinoids, kappa opioids, and a ceramide axis have all been shown to have potential as novel therapeutic targets without the negative effects of opioids. Summary: Review of the most recent and promising studies involving CIBP, specifically within murine models. Cancer pain has been reported by 30–50% of all cancer patients and even more in late stages, however the standard of care is not effective to treat CIBP. The complicated and chronic nature of this type of pain response renders over the counter analgesics and opioids largely ineffective as well as difficult to use due to unwanted side effects. Preclinical studies have been standardized and replicated while novel treatments have been explored utilizing various alternative receptor pathways: cysteine/glutamate antiporter system, x c − , cannabinoid type 1 receptor, kappa opioids, and a ceramide axis sphingosine-1-phosphate/sphingosine-1-phosphate receptor 1.

15 January 2023 in Medical Education Online
Verified
Journal Article
Open access
AMAnthony J. Maltagliati
Anthony J. Maltagliati
JPJoshua H. Paree
Joshua H. Paree
KMKadian L. McIntosh
Kadian L. McIntosh
KMKevin F. Moynahan
Kevin F. Moynahan
Todd W VanderahTodd W Vanderah
Todd W Vanderah
Pre-clerkship curricula of most Liaison Committee on Medical Education (LCME)-accredited medical schools are divided into blocks by organ system, leaving a significant amount of information susceptible to loss due to prolonged nonuse. We describe the implementation of a formal Spiral Curriculum that periodically revisits material from previous blocks. Learners were surveyed on receptivity to the curriculum across three graduating classes at a single medical school. Medical school graduate classes of 2020, 2021, and 2022 were surveyed at the end of their pre-clerkship years (2018–2020). The class of 2022 actually received the Spiraled Curriculum intervention, for which the authors created 500 board exam style multiple-choice questions, periodically administered via mandatory in-class sessions ranging from 10 to 20 questions reviewing content from previous blocks with designated expert faculty. Response rates were 36% (n = 46), 45% (n = 52), and 32% (n = 40) for classes of 2020, 2021, and 2022, respectively. On a Likert scale (1 = strongly disagree, 5 = neutral, 10 = strongly agree), the classes of 2020, 2021, and 2022 provided statistically significant differences in their belief that a Spiraled Curriculum would/did help them retain information as 8.2 (SD 1.7), 8.2 (SD 2.2), and 5.0 (SD 3.0) (n < 0.05). All classes endorsed neutral confidence in the existing pre-clerkship curriculum in themselves to prepare for United Stated Medical Licensing Examination (USMLE) Step 1, and in their retention of previous block material with no statistically significant differences between classes. USMLE Step 1 scores did not differ significantly between classes (n = 0.21). Those who did not receive the Spiral Curriculum were highly receptive to it in theory, while those who actually received the intervention gave a neutral rating. Per survey comments, implementation of a Spiraling Curriculum would ideally be administered as either team-based or self-directed activities, and a Spiraling Curriculum may be difficult to implement in accelerated (18 month) pre-clerkship formats. Practice points

Zhanette Hope CoffeeZhanette Hope Coffee
Zhanette Hope Coffee
KCKevin Cheng
Kevin Cheng
MSMaribeth Slebodnik
Maribeth Slebodnik
KMKimberly Mulligan
Kimberly Mulligan
CYChong Ho Yu
Chong Ho Yu
JGJudith S. Gordon
Judith S. Gordon
Despite the lack of evidence, opioids are still routinely used as a solution to long-term management for chronic noncancer pain (CNCP). Given the significant risks associated with long-term opioid use, including the increased number of unregulated opioid pills at large in the opioid ecosystem, opioid cessation or reduction may be the desired goal of the patient and clinician. Viable nonpharmacological interventions (NPIs) to complement and/or replace opioids for CNCP are needed. Comprehensive reviews that address the impact of NPIs to help adults with CNCP reduce opioid use safely are lacking. We conducted a literature search in PubMed, CINAHL, Embase, PsycINFO, and Scopus for studies published in English. The initial search was conducted in April 2021, and updated in January 2024. The literature search yielded 19,190 relevant articles. Thirty-nine studies met the eligibility criteria and underwent data extraction. Of these, nineteen (49%) were randomized controlled trials, eighteen (46%) were observational studies, and two (5%) were secondary analyses. Among adults with CNCP who use opioids for pain management, studies on mindfulness, yoga, educational programs, certain devices or digital technology, chiropractic, and combination NPIs suggest that they might be an effective approach for reducing both pain intensity and opioid use, but other NPIs did not show a significant effect (e.g., hypnosis, virtual reality). This review revealed there is a small to moderate body of literature demonstrating that some NPIs might be an effective and safe approach for reducing pain and opioid use, concurrently.

Verified
Journal Article
Open access
PDF file
MSMaha Sulaiman
Maha Sulaiman
WAWafaa Alabsi
Wafaa Alabsi
LSLajos Szabo
Lajos Szabo
MHMeredith Hay
Meredith Hay
RPRobin Polt
Robin Polt
Todd W VanderahTodd W Vanderah
Todd W Vanderah
Pain is the most significant impairment and debilitating challenge for patients with bone metastasis. Therefore, the primary objective of current therapy is to mitigate and prevent the persistence of pain. Thus, cancer-induced bone pain is described as a multifaceted form of discomfort encompassing both inflammatory and neuropathic elements. We have developed a novel non-addictive pain therapeutic, PNA6, that is a derivative of the peptide Angiotensin-(1-7) and binds the Mas receptor to decrease inflammation-related cancer pain. In the present study, we provide evidence that PNA6 attenuates inflammatory, chemotherapy-induced peripheral neuropathy (CIPN) and cancer pain confined to the long bones, exhibiting longer-lasting efficacious therapeutic effects. PNA6, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-Lact)-amide, was successfully synthesized using solid phase peptide synthesis (SPPS). PNA6 significantly reversed inflammatory pain induced by 2% carrageenan in mice. A second murine model of platinum drug-induced painful peripheral neuropathy was established using oxaliplatin. Mice in the oxaliplatin-vehicle treatment groups demonstrated significant mechanical allodynia compared to the oxaliplatin-PNA6 treatment group mice. In a third study modeling a complex pain state, E0771 breast adenocarcinoma cells were implanted into the femur of female C57BL/6J wild-type mice to induce cancer-induced bone pain (CIBP). Both acute and chronic dosing of PNA6 significantly reduced the spontaneous pain behaviors associated with CIBP. These data suggest that PNA6 is a viable lead candidate for treating chronic inflammatory and complex neuropathic pain.

21 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MSMaha Sulaiman
Maha Sulaiman
WAWafaa Alabsi
Wafaa Alabsi
LSLajos Szabo
Lajos Szabo
MHMeredith Hay
Meredith Hay
RPRobin Polt
Robin Polt
Todd W VanderahTodd W Vanderah
Todd W Vanderah
The renin-angiotensin system (RAS) plays a role in cardiovascular homeostasis and hydro-electrolyte balance influencing organ function throughout the body. The classical view of RAS focused on a single biologically active metabolite, the octapeptide angiotensin (Ang)ll, created by the Angiotensin-converting enzyme (ACE). The past two decades have revealed new functions for intermediate products of the RAS beyond their role as substrates. Angiotensin 1-7 (Ang-(1—7), a RAS peptide product with actions at the Mas receptor, reportedly prevents cardiovascular disease-induced cognitive decline and cancer-induced bone pain (CIBP). However, Ang-(1—7) has a short half-life in vivo; here, we hypothesized that activating the MasR1 with a lactoside Ang-(1—7) analogue- PNA6-would attenuate inflammatory, cancer pain confined to the long bones, and chemotherapy-induced peripheral neuropathy (CIPN) for a longer-lasting efficacious therapeutic effect. PNA6, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-Lact)-amide, was successfully synthesized on solid phase peptide synthesis (SPPS). PNA6 significantly reversed inflammatory pain induced by 2% carrageenan in mice. In a second study modeling a complex pain state, E0771 breast adenocarcinoma cells were implanted into the femur of female C57BLK/6J wild-type mice to induce cancer-induced bone pain (CIBP). Both acute and chronic dosing of PNA6 significantly reduced the spontaneous pain behaviors associated with CIBP. A third murine model of platinum drug-induced painful peripheral neuropathy was established using oxaliplatin. Mice in the oxaliplatin-vehicle treatment groups demonstrated significant mechanical allodynia compared to oxaliplatin- PNA6 treatment group mice. These data suggest that PNA6 is a viable lead candidate for treating chronic inflammatory and complex neuropathic pain.

21 October 2026 in Frontiers in Pain Research
Verified
Journal Article
Open access
PDF file
NMNikhil C. Mathur
Nikhil C. Mathur
EVEthan Villaroel
Ethan Villaroel
IVIsabella Villaroel
Isabella Villaroel
ELErika Liktor-Busa
Erika Liktor-Busa
KKKelly L. Karlage
Kelly L. Karlage
Todd W VanderahTodd W Vanderah
Todd W Vanderah
Introduction: Cancer-induced bone pain (CIBP) is a common symptom among patients with metastasized cancer, however, health professionals often face challenges in managing patients’ pain. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a DAMP overexpressed in metastatic breast carcinoma that binds to Toll-Like Receptor 4 (TLR4) to potentially trigger a signaling cascade through Nuclear Factor kappa β (NFk- β ) inducing inflammation, osteoclastogenesis, and contributing to CIBP. To assess the impact of eNAMPT on CIBP and to identify alternative therapeutic options, ALT-100, an eNAMPT-neutralizing monoclonal antibody, was tested in murine and cell-based models. Methods: First, eNAMPT synthesis and secretion by EO771 breast adenocarcinoma cells and its modulation by ALT-100 were assessed using eNAMPT ELISA. Next, recombinant eNAMPT-induced osteoclastogenesis and its inhibition by ALT-100 were evaluated in RAW 264.7 osteoclast precursor cells using TRAP staining. In vivo , female C57BL/6J mice underwent intramedullary femoral injection of EO771 cells to establish CIBP or SHAM surgery. One week later, mice received ALT-100 (4 mg/kg, ip) or saline control, followed by longitudinal assessment of pain-related behaviors and femoral radiographs. Results: The eNAMPT ELISA assay revealed that EO771 cells synthesize and secrete eNAMPT in a time-dependent manner maximal at 48 h, which were reduced by ALT-100 mAb. In RAW 264.7 cells, recombinant eNAMPT significantly increased TRAP activity, while co-administration of ALT-100 significantly reduced this effect. In the murine CIBP model, ALT-100 significantly reduced pain-related behaviors compared to saline control mice in the cancer group. Moreover, radiographic analysis demonstrated that ALT-100 mitigates cancer-induced bone loss. Discussion: These data show that ALT-100 exhibits antinociceptive effects in a CIBP murine model and inhibits eNAMPT-induced osteoclast differentiation. Our results indicate that blockade of eNAMPT can potentially serve as an alternative clinical strategy for treating CIBP.